BGB 290

Drug Profile

BGB 290

Alternative Names: BeiGene-290; BGB-290; PARP-Tankyrase programme - BeiGene; PARPi - BeiGene

Latest Information Update: 15 Jun 2017

Price : $50

At a glance

  • Originator BeiGene
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Solid tumours

Most Recent Events

  • 05 Jun 2017 Initial efficacy and adverse events data from a phase I trial in Solid tumours presented at the American Society for Clinical Oncology Annual Meeting (ASCO-2017)
  • 15 May 2017 BeiGene plans a phase Ib/II trial for Glioblastoma (Combination therapy, First-line therapy, In adults, In the elderly, Newly diagnosed, Recurrent, Refractory metastatic disease) in USA (NCT03150862)
  • 15 May 2017 BeiGene plans a phase I/II trial for Solid tumours (Metastatic disease, Late-stage disease, Combination therapy) (NCT03150810)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top